Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan.
In this multi-center study, we report the patient selection criteria for and preliminary oncologic outcomes associated with intraoperative radiotherapy (IORT) delivered by the Xoft Axxent® eBx® system for early-stage breast cancer in Taiwan.Patients with early breast cancer in Taiwan received breast...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5667880?pdf=render |
id |
doaj-61f3df13a062466d92e331f81606053b |
---|---|
record_format |
Article |
spelling |
doaj-61f3df13a062466d92e331f81606053b2020-11-24T21:50:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018587610.1371/journal.pone.0185876Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan.Hung-Wen LaiLiang-Chih LiuFu OuyangChung-Chin YaoHsiang-Chun JanYa-Herng ChangChi-Wen TuDar-Ren ChenTsui-Fen ChengYen-Dun TzengHuan-Ming HsuMing-Hsin YehYao-Chung WuPo-Sheng YangHung-Bun LamMing-Feng HouFang-Ming ChenIn this multi-center study, we report the patient selection criteria for and preliminary oncologic outcomes associated with intraoperative radiotherapy (IORT) delivered by the Xoft Axxent® eBx® system for early-stage breast cancer in Taiwan.Patients with early breast cancer in Taiwan received breast conserving surgery and received IORT with Xoft Axxent® eBx® System during 2013-2015 was search from database of Taiwan IORT study cooperative group (T-IORTSCG). Patients' clinicopathologic characteristics and early post-operative results were collected and reported.During the study period, 26 hospitals in Taiwan performed a total of 261 Xoft IORT procedures for breast cancer. The mean age of them was 52.9 ± 9.8 years (37-72), and tumor size was 1.5 ± 0.8 cm (0.1-4.2 cm) for invasive cancer and 1.2 ± 0.8 cm (range, 0.2-3.0 cm) for ductal carcinoma in situ (DCIS) lesions. Lymph node metastasis was found in 6 (2.3%) patients. The patients received IORT in Taiwan differed markedly from those used in the ELIOT and TARGIT-A studies. Specifically, patients selected for IORT in Taiwan tended to be younger, their tumors tended to be larger and the prevalence of lymph node metastasis tended to be lower. Among these 261 patients, 8 (3.1%) patients required whole breast radiotherapy. During a mean follow up of 15.6 months, locoregional recurrence was observed in 2 (0.8%) patients.In real world experience, patients received IORT differed quite significantly with criteria formulated by trials. The preliminary results of IORT in Taiwan showed it is well acceptable by patients and clinicians.http://europepmc.org/articles/PMC5667880?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hung-Wen Lai Liang-Chih Liu Fu Ouyang Chung-Chin Yao Hsiang-Chun Jan Ya-Herng Chang Chi-Wen Tu Dar-Ren Chen Tsui-Fen Cheng Yen-Dun Tzeng Huan-Ming Hsu Ming-Hsin Yeh Yao-Chung Wu Po-Sheng Yang Hung-Bun Lam Ming-Feng Hou Fang-Ming Chen |
spellingShingle |
Hung-Wen Lai Liang-Chih Liu Fu Ouyang Chung-Chin Yao Hsiang-Chun Jan Ya-Herng Chang Chi-Wen Tu Dar-Ren Chen Tsui-Fen Cheng Yen-Dun Tzeng Huan-Ming Hsu Ming-Hsin Yeh Yao-Chung Wu Po-Sheng Yang Hung-Bun Lam Ming-Feng Hou Fang-Ming Chen Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. PLoS ONE |
author_facet |
Hung-Wen Lai Liang-Chih Liu Fu Ouyang Chung-Chin Yao Hsiang-Chun Jan Ya-Herng Chang Chi-Wen Tu Dar-Ren Chen Tsui-Fen Cheng Yen-Dun Tzeng Huan-Ming Hsu Ming-Hsin Yeh Yao-Chung Wu Po-Sheng Yang Hung-Bun Lam Ming-Feng Hou Fang-Ming Chen |
author_sort |
Hung-Wen Lai |
title |
Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. |
title_short |
Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. |
title_full |
Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. |
title_fullStr |
Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. |
title_full_unstemmed |
Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. |
title_sort |
multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (iort) with the xoft axxent® ebx® system for the management of early stage breast cancer in taiwan. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
In this multi-center study, we report the patient selection criteria for and preliminary oncologic outcomes associated with intraoperative radiotherapy (IORT) delivered by the Xoft Axxent® eBx® system for early-stage breast cancer in Taiwan.Patients with early breast cancer in Taiwan received breast conserving surgery and received IORT with Xoft Axxent® eBx® System during 2013-2015 was search from database of Taiwan IORT study cooperative group (T-IORTSCG). Patients' clinicopathologic characteristics and early post-operative results were collected and reported.During the study period, 26 hospitals in Taiwan performed a total of 261 Xoft IORT procedures for breast cancer. The mean age of them was 52.9 ± 9.8 years (37-72), and tumor size was 1.5 ± 0.8 cm (0.1-4.2 cm) for invasive cancer and 1.2 ± 0.8 cm (range, 0.2-3.0 cm) for ductal carcinoma in situ (DCIS) lesions. Lymph node metastasis was found in 6 (2.3%) patients. The patients received IORT in Taiwan differed markedly from those used in the ELIOT and TARGIT-A studies. Specifically, patients selected for IORT in Taiwan tended to be younger, their tumors tended to be larger and the prevalence of lymph node metastasis tended to be lower. Among these 261 patients, 8 (3.1%) patients required whole breast radiotherapy. During a mean follow up of 15.6 months, locoregional recurrence was observed in 2 (0.8%) patients.In real world experience, patients received IORT differed quite significantly with criteria formulated by trials. The preliminary results of IORT in Taiwan showed it is well acceptable by patients and clinicians. |
url |
http://europepmc.org/articles/PMC5667880?pdf=render |
work_keys_str_mv |
AT hungwenlai multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT liangchihliu multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT fuouyang multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT chungchinyao multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT hsiangchunjan multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT yaherngchang multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT chiwentu multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT darrenchen multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT tsuifencheng multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT yenduntzeng multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT huanminghsu multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT minghsinyeh multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT yaochungwu multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT poshengyang multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT hungbunlam multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT mingfenghou multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan AT fangmingchen multicenterstudyonpatientselectionforandtheoncologicsafetyofintraoperativeradiotherapyiortwiththexoftaxxentebxsystemforthemanagementofearlystagebreastcancerintaiwan |
_version_ |
1725884746645372928 |